We estimate the post-release economic effects of participation in prison-based General Educational Development (GED) programs using a panel of earnings records and a rich set of individual information from administrative data in the state of Florida. Fixed effects estimates of the impact of participating in the GED education program show post-release quarterly earnings gains of about 15 percent...

background and aim : the quick speech in noise (q-sin) test have been designed to evalu­ate individuals’ ability to recognize speech in noise. this study established to evaluate the test-retest reliability and equivalency of the five test lists of the persian q-sin test in subjects with sensory hearing loss (shl) and normal hearing individuals. methods : this cross-sectional study was per­forme...

This study investigated whether ethoxyresorufin-O-deethylase (EROD) activity in rainbow trout exposed to mixtures of polycyclic aromatic hydrocarbons (PAHs) could be predicted from induction equivalency factors (IEF). The test PAHs were classified into strong and weak inducers on the basis of similar exposure-response curves. Induction equivalency factors of strong inducers, based on benzo[k]fl...

The first gas phase structure of a silanetriol, tert-butylsilane-triol [(t)BuSi(OH)(3)], determined by gas electron diffraction (GED), is reported. Quantum chemical calculations have been performed to elucidate potential intermolecular interactions between silanetriol molecules in the gas phase. The results are set into contrast to solid state structures of (t)BuSi(OH)(3) and related compounds.

Bioequivalence (BE) is required for approving a generic drug. The two one-sided tests procedure (TOST, or the 90% confidence interval approach) has been used as the mainstream methodology to test average BE (ABE) on pharmacokinetic parameters such as the area under the blood concentration-time curve and the peak concentration. However, for highly variable drugs (%CV > 30%), it is difficult to d...

III. LINGERING PROBLEMS FROM FESTO AND JOHNSON & JOHNSTON...........................................................................................516 A. Effects of Festo and Johnson & Johnston on the Patent System ................................................................................516 B. Inequitable Outcomes and Unfairness to Patent Owners ............................................

64 Pharmaceutical Technology SEPTEMBER 2005 Don Chambers, PhD,* is the senior director of analytical development for Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, NJ 07033, tel. 908.740.2318, fax 908.740.2107, donald. [email protected]. Gregg Kelly, PhD, is a senior principal scientist for Pfizer, Inc. (Groton, CT). Giselle Limentani, PhD, is a director of product ...